A new “BioShield Program” has been launched by Orgenesis (Nasdaq: ORGS), aimed at accelerating the discovery of antibodies to combat viral infections like COVID-19.
The Maryland, USA-based cell and gene specialist wants to mitigate the spread of such viruses and raise preparedness in the fight against emerging outbreaks.
The firm plans to leverage its POCare anti-viral technologies as part of the program, including the exploration of alternative and breakthrough processes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze